Pantoprazole, esomeprazole and dexlansoprazole: how the PPIs differ

Proton pump inhibitors (PPIs) reduce stomach acid by blocking the H⁺/K⁺-ATPase — the “proton pump” — in the parietal cells of the stomach. They are first-line treatment for gastro-oesophageal reflux disease (GERD) and erosive oesophagitis. The molecules share a mechanism, but their labels differ on three practical points: when to take them, how the formulation releases the drug, and interactions.

At a glance

	Pantoprazole 40 mg	Esomeprazole 40 mg	Dexlansoprazole 30 mg
Formulation	Delayed-release tablet	Delayed-release capsule	Dual delayed-release capsule
Timing (US label)	With or without food; swallow whole	At least 1 hour before a meal	Without regard to food
Clopidogrel	No dose adjustment needed	Avoid combination	No clinically important effect
Deeva Light product	DEPRA-GR Tablet	DESSO-40 Capsule	DXD-60 Capsule

Timing with meals

Advice on timing differs between countries. The US label allows pantoprazole delayed-release tablets to be taken with or without food, while the UK product information advises taking them one hour before a meal. Esomeprazole should be taken at least one hour before meals. Dexlansoprazole’s capsule contains two types of enteric-coated granules that dissolve at different pH levels, producing two peaks in blood levels (about 1–2 hours and 4–5 hours after the dose); its label allows it to be taken without regard to food.

The clopidogrel question

Clopidogrel needs the liver enzyme CYP2C19 to become active. Omeprazole and esomeprazole inhibit that enzyme, and the clopidogrel label advises avoiding them together because they significantly reduce its antiplatelet effect. The same label notes that pantoprazole and dexlansoprazole had less effect. For a patient on clopidogrel who needs a PPI, pantoprazole or dexlansoprazole is the usual choice — decided by the prescriber.

Indications on the labels

Healing erosive oesophagitis: pantoprazole 40 mg daily up to 8 weeks; esomeprazole 20 or 40 mg daily for 4–8 weeks; dexlansoprazole uses 60 mg daily for healing and 30 mg for maintenance and non-erosive GERD.
H. pylori eradication: esomeprazole (US) and pantoprazole (UK/EU) carry this indication as part of combination therapy with antibiotics. Dexlansoprazole does not.
Zollinger-Ellison syndrome: pantoprazole and esomeprazole.

When a prokinetic is added

Some patients with reflux or dyspepsia also have bloating, fullness and nausea from slow gastric emptying. Two prokinetics are used for this in the region:

Levosulpiride — a dopamine D2 receptor antagonist, combined with pantoprazole in DEPRA-L Capsule. Because it blocks D2 receptors centrally, it can raise prolactin (breast discharge, menstrual changes); patients should report these symptoms. It is not an FDA-approved medicine.
Itopride — combines D2 antagonism with acetylcholinesterase inhibition. In clinical trials it was used at 50 mg three times daily for functional dyspepsia. It is metabolised by flavin monooxygenase rather than CYP450, and did not prolong the QT interval in studies.

Counselling points for long-term use

PPI labels list risks that grow with long-term, high-dose use. Review the need for continued therapy regularly and counsel patients about:

Clostridioides difficile-associated diarrhoea, particularly in hospitalised patients
Bone fractures of the hip, wrist or spine with long-term or multiple daily doses
Low magnesium after three months or more of use
Vitamin B12 deficiency with long-term daily use

Explore the full gastroenterology range.

Sources

This article is for healthcare professionals and trade customers and does not replace the product insert or a prescriber’s judgement. Always follow the prescribing information supplied with the product.